Drugs · acquisition-cost intelligence
Methotrexate
METHOTREXATE SODIUM· ingredient methotrexateOther immunosuppressants· METHOTREXATE SODIUM 25 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$3.36
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other methotrexate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Methotrexate | $0.16406 | −$3.20 |
| Methotrexate | $1.23 | −$2.13 |
| methotrexate | $2.57 | −$0.79180 |
| Rasuvo | $482.29 | +$478.93 |
Medicare Part D coverage · CY2026
On 325 plan formularies · typical tier 2
Prior auth 34% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.